miRNAs as Predictive Factors in Early Diagnosis of Gestational Diabetes Mellitus

Ilona Juchnicka[1], Mariusz Kuźmicki[1*], Magdalena Niemira[2], Agnieszka Bielska[2], Iwona Sidorkiewicz[2], Monika Zbucka-Krętowska[3], Adam Jacek Krętowski[2] and Jacek Szamatowicz[1]

[1] Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, Bialystok, Poland, [2] Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland, [3] Department of Gynecological Endocrinology and Adolescent Gynecology, Medical University of Bialystok, Bialystok, Poland

Introduction: Circulating miRNAs are important mediators in epigenetic changes. These non-coding molecules regulate post-transcriptional gene expression by binding to mRNA. As a result, they influence the development of many diseases, such as gestational diabetes mellitus (GDM). Therefore, this study investigates the changes in the miRNA profile in GDM patients before hyperglycemia appears.

Materials and Methods: The study group consisted of 24 patients with GDM, and the control group was 24 normoglycemic pregnant women who were matched for body mass index (BMI), age, and gestational age. GDM was diagnosed with an oral glucose tolerance test between the 24th and 26th weeks of pregnancy. The study had a prospective design, and serum for analysis was obtained in the first trimester of pregnancy. Circulating miRNAs were measured using the NanoString quantitative assay platform. Validation with real time-polymerase chain reaction (RT-PCR) was performed on the same group of patients. Mann-Whitney U-test and Spearman correlation were done to assess the significance of the results.

Results: Among the 800 miRNAs, 221 miRNAs were not detected, and 439 were close to background noise. The remaining miRNAs were carefully investigated for their average counts, fold changes, p-values, and false discovery rate (FDR) scores. We selected four miRNAs for further validation: miR-16-5p, miR-142-3p, miR-144-3p, and miR-320e, which showed the most prominent changes between the studied groups. The validation showed up-regulation of miR-16-5p (p<0.0001), miR-142-3p (p=0.001), and miR-144-3p (p=0.003).

Conclusion: We present changes in miRNA profile in the serum of GDM women, which may indicate significance in the pathophysiology of GDM. These findings emphasize the role of miRNAs as a predictive factor that could potentially be useful in early diagnosis.

Keywords: gestational diabetes, miR-16-5p, miR-142-3p, miR-144-3p, epigenetics, serum profiling, biomarkers, miRNA

INTRODUCTION

Gestational Diabetes Mellitus (GDM) is one of the leading diseases during pregnancy. According to the newest edition of the International Diabetes Federation (IDF) Diabetes Atlas, GDM affected nearly 17 million live births in the last year (1). Extensive hormonal changes during pregnancy are one of the reasons for increased insulin resistance. For instant, the hyperestrogenemic state observed during pregnancy contributes to alterations in insulin sensitivity. Estrogen may bind directly to insulin or its receptors, making them unavailable for insulin (2). Furthermore, human placental lactogen (hPL) decreases maternal insulin sensitivity in order to provide the fetus with sufficient nutrition (3). When the insulin release is insufficient and a glucose-lowering response is not achieved, the risk of GDM development is high (4). Meta-analysis showed that the most relevant risk factors for GDM are high BMI and thyroid disease (5). Another risk factors are increased fasting glycemia in the first trimester of pregnancy, abdominal obesity, family history of diabetes mellitus, genetic factors, environmental factors including lifestyle and diet, comorbidities like polycystic ovary syndrome (PCOS) (6, 7). Combinations of several risk factors more confidently indicate women at high risk of developing GDM (8). Considering, that utility of risk factors, such as i.e first-trimester fasting blood glucose concertation is limited (9), it is essential to search for the most ideal non-invasive biomarker for early GDM detection or even a predisposition to develop GDM.

MiRNAs are a group of non-encoding RNA molecules of 19-22 nucleotides that play a key role in the regulation of post-transcriptional gene expression (10, 11). Notably, one miRNA has the ability to bind with many genes by recognizing the not-necessarily complementary sequence at the end of the 3'-untranslated region (3'UTR) of the target mRNA (12). In this way, endogenous miRNAs control the expression of many genes and influence the processes that take place in cells, such as cell metabolism, proliferation, DNA repair, and apoptosis. Furthermore, data suggest that extracellular miRNAs act as modulators during physiological and pathological processes by transferring information between cells (13). Depending on which gene that the miRNA impacts, it can be either a stimulator or a suppressor of a pathological state (14).

MiRNA is detectable in various biological fluids, such as blood, urine, tears, saliva, and cerebrospinal, amniotic, or synovial fluid (15). In contrast to other RNA molecules, an important feature of miRNA is their stability and resistance to external factors, such as RNAse (16). This is due to the form in which they occur in biofluids. MiRNA forms complexes with lipoproteins or proteins (17). Moreover, the protective effect may be a result of their encasement inside membrane structures like exosomes, microparticles, or apoptotic bodies (17, 18). It has also been shown that repeated cycles of freezing and thawing do not cause significant changes in miRNA content in the serum (19). These mechanisms and non-invasive collection mean that circulating miRNAs have good potential as a biomarker.

In recent years, there have been a number of reports on changes in miRNA expression in various diseases, including metabolic disorders. One of the ultimate purposes of most of the studies is finding miRNAs that could help with identifying pathological processes, estimate the success of a patient's response to therapy (20), or support the identification of high-risk groups (21). Zhao et al. were some of the first to describe changes in the sera of pregnant women with GDM (22). Since that time, many scientists have focused on changes in miRNA expression in GDM, but the available data are not consistent. Thus, the purpose of this study was to compare the miRNA expression profile in a group of patients in the first trimester of pregnancy and GDM diagnosed in the second trimester of pregnancy with that of a healthy control group. Then, based on these results, we sought to identify potential biomarkers of early GDM diagnosis.

MATERIALS AND METHODS

Study Population

Project included four meetings, in the first trimester (9-12 week), in the second (24-26 week), in the third trimester (34-37 week) and three months after delivery. During the first trimester of pregnancy, fasting venous blood samples were collected into S-Monovette Gel Clotting Activator tubes (Sarstedt, Numbrecht, Germany). After complete clotting and centrifugation, the serum to be used for miRNA analysis was separated, transferred into DNase- and RNase-free tubes (Eppendorf, Hamburg, Germany), and stored at -80°C until they were assayed. To diagnose GDM all patients underwent a 75g oral glucose tolerance test (OGTT) in the second trimester, between 24th and 27th weeks of pregnancy. GDM was diagnosed according to the World Health Organization (WHO) criteria (23). In the experiment the serum from the first trimester was examined while both groups revealed normoglycemia. The study group (GDM) (n=24) and control group with normal glucose tolerance (NGT) (n=24) were carefully matched for pre-pregnancy body mass index (BMI), age, and gestational age. Women with the history of GDM, stillbirth, childbirth with congenital anomalies, pregnancy-induced hypertension, preeclampsia, cholestasis, premature delivery, acute or chronic inflammation, multiple pregnancy, pre-existing glucose intolerance, and active smokers were excluded from the study. Written informed consent was obtained from each patient, and the study was approved by the local ethics committee (Medical University of Bialystok).

Biochemical Methods

Plasma glucose concentrations were measured using an enzymatic method with hexokinase (Cobas C11, Roche Diagnostics Ltd, Switzerland), and the serum insulin level was evaluated by an immunoradiometric method (DiaSource Europe SA, Belgium) using a Wallac Wizard 1470 Automatic Gamma Counter (Perkin Elmer, Life Science, Turku, Finland). Glycated hemoglobin (HbA1c) was assayed by high-performance liquid chromatography (Bio-Rad D-10, Bio-Rad Laboratories, Hercules, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) and homeostatic model assessment of β-cell function were calculated for all women in each trimester

of pregnancy. Moreover, in the second trimester, insulin sensitivity was measured using the OGTT insulin sensitivity index of Matsuda and DeFronzo (ISI_{OGTT}).

miRNA Isolation

MiRNA was isolated using the miRNeasy Serum/Plasma Advanced Kit (Qiagen, Germany) by following the manufacturer's protocol. The isolation method is based on the innovative spin-column separation method with a silica membrane. The use of this kit allows us to obtain miRNA of high quality and purity, which is necessary for the subsequent stages of the experiment. The content of miRNA in extracted samples was checked with a fluorometer (Qubit 3.0, Thermo Fisher Scientific, Waltham, USA).

Nanostring Analysis

For miRNA profiling, we used NanoString technology with a digital color-coded barcode for direct and multiplex marking of target sequences of 800 miRNAs. The method uses about 50 nucleotide probes per 1 miRNA. At the 5' end, a set of 6 fluorescently labeled "barcodes" is placed, and at the 3' end, a "capture probe" with biotin is placed. One set allows for simultaneous determination of 800 miRNAs in 12 samples.

Due to the procedure used, the cDNA synthesis and amplification stages were omitted, which allows us to reduce the probability of laboratory error. The results were read out on a NanoString nCounter scanner. The first stage of the analysis was the hybridization of individual miRNAs with specific probes, and the next was the purification and placing of hybridized samples on a specially standardized plate. The last stage was reading of the obtained results. The method allowed for the exact number of miRNA copies to be specified in each sample.

RT-PCR Validation

Validation of the results was carried out on the same group of patients (24 women in the NGT control group and 24 in GDM study group). To validate the results, the real-time PCR method was used. In the first step, reverse transcription was performed to transcribe miRNA to cDNA using the miRCURY LNA RT Kit (Qiagen, Germany) in accordance with the manufacturer's

procedure on a C1000 Touch Thermal Cycler (Bio-Rad Laboratories, Hercules, USA). Subsequently, we performed RT PCR reaction using the miRCURY LNA SYBR Green PCR Kit (Qiagen, Germany) and specific primers for each of the analyzed miRNAs (Qiagen, Germany) on a LightCycler 480 thermal cycler (Roche Diagnostics Ltd, Switzerland). Expression of circulating miRNAs was evaluated using miR-103a-3p as an endogenous control gene. All samples were assayed in duplicate, and the comparative Ct method was used to calculate the relative changes in gene expression.

Data Analysis

Analysis of raw miRNA data obtained using NanoString technology was performed in nSolver software version 4.0. Data were normalized by the average geometric mean of the top 100 probes detected. The miRNAs' expression values in RT-PCT validation were calculated based on the $\Delta\Delta CT$ method. The differences in miRNA expressions between groups were calculated by the Mann-Whitney U test using Statistica 13 for Microsoft Software (StatSoft Inc., Tulsa, USA). The relationships between variables were tested using the Spearman rank correlation coefficient. Results were considered statistically significant with p-value less than 0.05.

RESULTS

Characteristics of the Groups Studied

The clinical characteristics of the studied groups are presented as medians and interquartile ranges (**Tables 1**, **2**). In the 1st trimester of pregnancy, there were no significant differences between groups. Women in both groups were normoglycemic. Most patients had normal pre-pregnancy BMI (n=10 in GDM group and n=11 in NGT group had BMI >25 kg/m^2 indicating overweight). In the 2nd trimester, groups revealed significant differences in fasted and post-loaded glucose measurements (glucose at 0, 30, 60, and 120 minutes: p=0.0001, p=0.0000, p=0.0000, and p=0.001, respectively). The GDM group had a higher insulin level at 60 minutes (p=0.02), insulin level at 120 minutes (p=0.004), and HOMA-IR (p=0.02). Fasting insulin and

TABLE 1 | Clinical characteristics of groups studied in the 1st trimester.

	NGT	GDM	p-value
n	24	24	
Age (years)	28 (26-31.5)	26 (24-30.5)	0.36
Pre-pregnancy BMI (kg/m²)	21.8 (20.0-28.2)	23.5 (21.6-26.8)	0.73
Gestational age (week)	11 (10-12)	10 (9.5-11)	0.24
Fasting glucose (mg/dl)	86 (84-88)	87.5 (85-90)	0.29
Fasting insulin (µU/ml)	10.7 (9.1-12.9)	11.3 (10.2-13.3)	0.25
HOMA-IR	2.3 (1.9-2.8)	2.5 (2.1-2.9)	0.18
HOMA-β	168.0 (145.5-187.5)	166.5 (146.9-201.0)	0.97
HbA1c (%)	5.0 (4.9-5.4)	5.0 (4.9-5.4)	0.98
Total cholesterol (mmol/l)	170 (149.5-191.5)	169.5 (156.5-186)	0.81
HDL-cholesterol (mmol/l)	81 (69.5-90.5)	73.5 (59.5-84.5)	0.19
LDL-cholesterol (mmol/l)	78.2 (64.3-91.6)	81 (64.9-95.3)	0.78
Triglycerides (mmol/l)	72 (60.5-109.5)	95.5 (68.5-118)	0.14

Data are shown as medians (interquartile range); The difference between NGT vs GDM group was compared with the Mann-Whitney U-test.

TABLE 2 | Clinical characteristics of groups studied in the 2nd trimester.

	NGT	GDM	P value
n	24	24	
Gestational age (week)	25 (25-26)	25 (25-26)	0.81
Fasting glucose (mg/dl)	82.5 (79-85)	92 (84-94)	0.0001
Glucose 30' (mg/dl)	127.5 (121-140)	158 (148-165)	< 0.0001
Glucose 60' (mg/dl)	122 (101.5-141.5)	169 (136.5-184)	< 0.0001
Glucose 120' (mg/dl)	105.5 (86-119)	125.5 (111.5-166)	0.001
Fasting insulin (μU/ml)	11.2 (8.6-13.3)	13.4 (10.1-18.2)	0.08
Insulin 30' (μU/ml)	74.2 (60.0-110.9)	80.1 (61.0-137.3)	0.62
Insulin 60' (μU/ml)	80.1 (54.3-107.2)	106.5 (74.2-174.0)	0.02
Insulin 120' (μU/ml)	56.0 (42.0-72.4)	108.8 (60.5-131.0)	0.004
HOMA-IR	2.3 (1.7-2.7)	3.0 (2.1-4.4)	0.02
HOMA-β	188.3 (168.8-282.0)	191.4 (149.4-240.3)	0.21
ISI OGTT	4.4 (3.4-5.4)	2.8 (2.1-3.9)	0.002
HbA1c (%)	4.8 (4.7-5.1)	4.9 (4.6-5.1)	0.74
Total cholesterol (mmol/l)	267.5 (203-287.5)	238 (188-257)	0.046
HDL-cholesterol (mmol/l)	96.5 (85.5-108.5)	85 (69.5-104.5)	0.13
LDL-cholesterol (mmol/l)	131 (101.4-171.2)	119.2 (85.0-140.4)	0.12
Triglycerides (mmol/l)	138 (120.5-170.5)	159 (135.5-204.5)	0.13

Data are shown as medians (interquartile range); The difference between NGT versus GDM group was compared with the Mann-Whitney U-test.

insulin after 30 minutes post-loading were also higher in the study group than in the NGT group, but the differences were insignificant. Moreover, the GDM group demonstrated lower ISI$_{OGTT}$ (p=0.002) and lower total cholesterol (p=0.046) than the NGT group.

Nanostring Profiling

We identified 28 miRNAs with expression that was significantly altered in the GDM group compared to the NGT group (p-value p<0.05). A careful analysis was done while considering not only the p-value, but also the false discovery rate, count ranges, fold change, and standard deviation. The results pointed out miR-16-5p (p=0.07), miR-142-3p (p=0.02), miR-144-3p (p=0.003), and miR-320e (p=0.02) for further validation. Changes in expression of miR-16-5p were not significant, whereas the mean value ranges of the counts were high (GDM=1056.03 versus NGT=756.86) with a wide standard deviation. Considering the method of simultaneous determination of many miRNAs and high count number, we decided to evaluate these molecules in further analysis.

Validation of the Results

NanoString results were validated by RT-PCR. The fold change of gene expression was calculated using the ΔΔCt method, and then log transformation was used to avoid a non-normal distribution of the results. We obtain confirmation of three miRNAs: miR-16-5p (p<0.0001), miR-142-3p (p=0.001), and miR-144-3p (p=0.003), which were significantly upregulated in the GDM group. No significant difference was observed for miR-320e (p=0.16) (**Figure 1**).

ROC curve analysis was performed for significant miRNAs in the 1st trimester of pregnancy as parameters to discriminate those who are at high risk group of developing GDM in the 2nd trimester of pregnancy (**Figure 2**). The AUC for miR-16-5p was 0.868 (95% confidence interval: 0.757–0.98; p<0.0001). AUC was 0.778 (95% confidence interval: 0.644-0.913; p<0.0001) for miR-

142-3p, and for miR-144-3p, AUC was 0.756 (95% confidence interval: 0.613-0.898; p=0.0004).

The relationships between prominent molecules' expressions and other variables were checked. Across the study population, 1st-trimester miR-16-5p expression correlated positively with fasting plasma glucose concentration in the 2nd trimester (R=0.56, p<0.05), plasma glucose concentration at 30 minutes post-loading (R=0.43, p<0.05), and HOMA-IR (R=0.36, p<0.05). Its expression negatively correlated with ISI$_{OGTT}$ (R=-0.34, p<0.05). MiRNA-142-3p positively correlated with plasma glucose levels post-loading with indexes as follows: 30 minutes (R=0.35, p<0.05), 60 minutes (R=0.37, p<0.05), and 120 minutes (R=0.36, p<0.05). Furthermore, there were correlations between miR-144-3p and plasma glucose concentration at 30 minutes post-loading (R= 0.41, p<0.05) and the plasma glucose level at 60 minutes post-loading (R=0.42, p<0.05), as well as a negative correlation with ISI$_{OGTT}$ (R=-0.33, p<0.05). Multiple regression analysis confirmed the dependences described except for the association of miR-16-5p and ISI$_{OGTT}$.

DISCUSSION

Researchers for many years have been trying to find the most ideal GDM biomarker. Among many significant features of the perfect indicator the most relevant is prediction value [24]. In case of GDM, the diagnosis nowadays is based on OGTT performed in the second trimester of pregnancy. Considering complications during pregnancy and delivery and a high risk of long-term complications for the child and the mother the GDM a biomarker revealed before changes in the glycemia occur seems to be crucial. Yoffe et al. [25] studied women between 9th and 11th weeks of pregnancy and showed an up-regulation of the miR-223 and miR-23a in plasma of GDM women. Interesting point of view was presented by Wander et al. connection of the miR-21-3p and miR-210-3p with GDM diagnosed in overweight and

FIGURE 1 | Box plots presented changes in expression of validated miRNAs between GDM group and NGT, **(A)** miR-16-5p (p<0.0001), **(B)/** miR-142-3p (p=0.001), **(C)** miR-144-3p (p=0.003) and **(D)** miR-320e (p=0.16). Data are presented by median indicated by line in each box and interquartile range. Maximum and minimum values are represented by whiskers.

obese women (26). Lamadrid-Romero et al. (27) showed that miR-183-5p was increased in every trimester in serum collected from women diagnosed with GDM. Simultaneously, the higher expression of miR-125b-3p, miR-200b-3p and miR-1290 were observed in the first trimester of pregnancy.

Our study shows that circulating miR-16-5p is upregulated in women before the onset of GDM, which is consistent with the results obtained by other studies. Zhu et al. (28) conducted studies on women at 16-19 weeks of pregnancy and described five molecules that were upregulated in the GDM group (e.g., miR-16-5p). Other studies reported increased expression of miR-16-5p in serum at 24 -28 weeks of pregnancy (29). Our results show this difference earlier between the 9th and 12th weeks of pregnancy. Moreover, we observed a positive correlation with HOMA-IR, which was also described by Cao et al. (29). Apart from miR-16-5p they described an up-regulation of the miR-17-5p and miR-20a-5p which was not observed in our experiment.

Attempts were made to determine miR-16-5p in leukocytes of women with GDM, but no significant differences were observed (30, 31). It turns out that high miR-16-5p expression also persists after pregnancy and correlates with high cardiovascular risk (32). This indicates that epigenetic changes during GDM are permanent, and women with a history of GDM are predisposed to the development type 2 diabetes (T2D) or cardiovascular disease in the following years (33). Another

study revealed increased expression of miR16-5p in overweight women before the 20th week of pregnancy. In contrast to previously cited reports, that study was conducted on European women (34). On the other hand, Martinez-Ibarra et al. demonstrated no significant changes in miR16-5p expression in serum collected in the 2nd trimester from GDM patients compared to NGT (35). A similar result was obtained by scientists from South Africa (36).

Considering that miRNAs could be related to genetic and environmental factors, Sørensen et al. proposed ethnicity as a potential explanation of differences in obtained results (34). Furthermore, they also suggested age, which is a known risk factor for GDM. The idea was supported by the correlation obtained between age and miR-16-5p expression. However, this dependence was not observed in our study.

Available data show that miR-16-5p is one of the most potent regulating molecules in the insulin-signaling pathway. Target genes for miR-16-5p encode insulin receptor substrate (IRS) proteins 1 and 2 and the insulin receptor itself (INSR) (37, 38). These proteins are crucial factors in a proper insulin signaling pathway, and their downregulation results in insulin resistance and metabolic disorders like diabetes. Additionally, miR-16-5p-targeted genes are involved in pancreatic β-cell proliferation and apoptosis (39). Target genes for miR-16-5p that are downregulated in type 2 diabetes are located in not only β-

FIGURE 2 | ROC curve for miRNA 16-5p (AUC = 0.868; $p < 0.0001$), miR-142-3p (AUC = 0.778; $p < 0.0001$) and for miR-144-3p (AUC = 0.756; $p = 0.0004$).

cells on pancreatic islets, but also peripheral blood mononuclear cells (PBMCs), the liver, and skeletal muscle (40).

An experimental study on *Cmah*-null mice showed that diabetic mice have upregulated miR-16-5p (among others) and downregulated IRS1, IRS2, AKT1, and mTOR mRNA (41). As a result of these changes, the crucial pathway in insulin-signaling PI3K-Akt-mTOR is dysregulated (42). Interestingly, Lee et al. (43) demonstrated a decrease in miR-16-5p expression in insulin-resistant skeletal muscle. Moreover, their *in-vitro* study revealed that miR-16-5p is involved in autophagy through controlling Bcl-2 protein synthesis. Also, an overexpression of miR-16-5p was accompanied by decreased mTOR content. Based on these findings, the inhibition of miR-16-5p expression might be important in treatment (44).

There are two reports on miR-142-3p in GDM. However, neither of these studies considers circulating human miR-142-3p. Collares et al. (45) described nine miRNAs (e.g., miR-142-3p) that are upregulated in PBMC obtained from type 1 diabetes (T1D), T2D, and gestational diabetes mellitus. The study did not associate the molecule with a specific gene, but its involvement in diabetes in general was noticeable. A study conducted on GDM-induced mice reported an overexpression of miR-142-3p in the circulating blood and embryonic tissue of GDM mice. Data demonstrated that *in-vitro* up-regulation of miR-143-3p has a positive effect on β-cells by promoting their proliferation, as well as inhibiting apoptosis by blocking the expression of p27, Bax, and caspase-3. In addition, bioinformatic analysis indicated forkhead box protein O1 (FOXO1) as a target gene for miR-142-3p (46). FOXO1 is

known as a multifunctional protein, and besides controlling glycogenolysis and gluconeogenesis, it regulates the differentiation of β-cells and promotes their apoptosis (47). This could be a self-protective effect of miR-142-3p.

Escalated expression of miR-142-3p has been described in obese adults as a parameter that is strongly associated with insulin, HOMA-IR, BMI, adiponectin, and leptin levels (48). Similar results were obtained in the case of childhood obesity, which revealed an increased concentration of miR-142-3p and a positive correlation with BMI, fat mass, adipose tissue distribution, and HOMA-IR. Interestingly, during a 3-year follow-up, upregulation in the expression of this molecule was observed solely in the serum of patients whose BMI remained stable or decreased (49). The data showed that the expression of the miR-142-3p may be sex-related.

Overexpression of miR-142-3p in the group of patients with pre-diabetes and diabetes was found only among women (50). The studies mentioned the possibility of age affecting these results because the male group was significantly younger. However, there may also be an influence from the distribution of adipose tissue according to the studies cited. In contrast to our study, Liang et al. showed a decreased expression of miR-142-3p in the serum of T2D patients, and a negative correlation with HOMA-IR was observed (51). In the present study, a positive correlation was revealed between miR142-3p and plasma glucose post-loading.

Another study has shown that miR-144-3p is upregulated in the liver, pancreas, skeletal muscle, adipose tissue, and blood of a diabetic rat model. The result was confirmed in circulating blood obtained from human T2D patients. In addition, a study of pancreatic cells cultured from rats revealed an increased level of miR-144-3p in a high glucose environment, and similar to miR-16-5p, it caused a downregulation of the expression of IRS1 (52). Moreover, the upregulation of miR-144-3p was observed in PBMCs collected from patients with T1D, T2D, and GDM (45). However, Akerman et al. (53) investigated patients with T1D and did not observe an elevation of serum miR-144-3p levels, but there was a positive correlation with islet antigen 2 antibodies (IA2A), indicating a possible relationship with the assessment of those at risk for T1D development.

Upregulated expression and a positive correlation with HOMA-IR of circulating miR-144-3p were observed in a Chinese cohort with impaired fasting glucose (IFG). Furthermore, high miR-144-3p was a predictor of T2D development (51). Interestingly, Wang et al. (54) showed an increased expression of miR-144-3p in T2D patients but solely in a Swedish population, not in patients from Iraq. Thus, this report confirms the contribution of environmental factors to epigenetic changes mentioned above. In a meta-analysis, Zhu and Leung (55) selected eight molecules as potential biomarkers of T2D, including miR-142-3p and miR-144-3p.

In summary, we found significantly upregulated expression of miR-16-5p, miR-142-3p, and miR-144-3p in the serum of patients in their 1st trimester of pregnancy who suffered from GDM diagnosed in the 2nd trimester. NanoString technology allowed us to study a wide panel of miRNA profiles. Considering

the research on miRNAs, a strong point of our experiment was the large number of patients in the studied groups. Although our findings are limited by the validation using the same group of women, our observations strongly suggest that changes taking place in the miRNA profile occur earlier than changes in glucose levels, and research on the more sensitive and specific biomarkers of GDM should be continued.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee Medical University of Bialystok.

The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

Conceptualization: IJ and MK. Methodology: MN, IJ, IS and AB. Formal analysis: MZK and AK. Writing—original draft preparation: IJ and MK. Writing—review and editing: AJK and JS. Supervision: JS and AJK. All authors contributed to the article and approved the submitted version.

FUNDING

REFERENCES

1. IDF Diabetes Atlas 2021. *IDF Diabetes Atlaa* (2021). Available at: https://diabetesatlas.org/atlas/tenth-edition/ (Accessed December 6, 2021).
2. Root-Bernstein R, Podufaly A, Dillon PF. Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding *In Vitro*. *Front Endocrinol (Lausanne)* (2014) 5:118. doi: 10.3389/fendo.2014.00118
3. Vasu S, Kumano K, Darden CM, Rahman I, Lawrence MC, Naziruddin B. MicroRNA Signatures as Future Biomarkers for Diagnosis of Diabetes States. *Cells* (2019) 8:1533. doi: 10.3390/cells8121533
4. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev* (2018) 98:2133–223. doi: 10.1152/physrev.00063.2017
5. Giannakou K, Evangelou E, Yiallouros P, Christophi CA, Middleton N, Papatheodorou E, et al. Risk Factors for Gestational Diabetes: An Umbrella Review of Meta-Analyses of Observational Studies. *PloS One* (2019) 14: e0215372. doi: 10.1371/journal.pone.0215372
6. Buchanan TA, Xiang A, Kjos SL, Watanabe R. What Is Gestational Diabetes? *Diabetes Care* (2007) 30:S105–11. doi: 10.2337/dc07-s201
7. Popova PV, Klyushina AA, Vasilyeva LB, Tkachuk AS, Vasukova EA, Anopova AD, et al. Association of Common Genetic Risk Variants With Gestational Diabetes Mellitus and Their Role in GDM Prediction. *Front Endocrinol (Lausanne)* (2021) 12:628582. doi: 10.3389/fendo.2021.628582
8. Popova PV, Grineva EN, Gerasimov AS, Kravchuk EN, Ryazantseva EM, Shelepova ES. The New Combination of Risk Factors Determining a High Risk of Gestational Diabetes Mellitus. *Minerva Endocrinol* (2015) 40:239–47.
9. Popova P, Tkachuk A, Dronova A, Gerasimov A, Kravchuk E, Bolshakova M, et al. Fasting Glycemia at the First Prenatal Visit and Pregnancy Outcomes in Russian Women. *Minerva Endocrinol* (2016) 41:477–85.
10. He L, Hannon GJ. MicroRNAs: Small RNAs With a Big Role in Gene Regulation. *Nat Rev Genet* (2004) 5:522–31. doi: 10.1038/nrg1379
11. Vishnoi A, Rani S. "MiRNA Biogenesis and Regulation of Diseases: An Overview". In: S Rani, editor. *MicroRNA Profiling: Methods and Protocols. Methods in Molecular Biology*. New York, NY: Springer (2017). p. 1–10. doi: 10.1007/978-1-4939-6524-3_1
12. Lewis BP, Shih I-H, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of Mammalian microRNA Targets. *Cell* (2003) 115:787–98. doi: 10.1016/s0092-8674(03)01018-3
13. Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. Circulating miRNAs: Cell–Cell Communication Function? *Front Genet* (2013) 4:119. doi: 10.3389/fgene.2013.00119
14. Croce CM. Causes and Consequences of microRNA Dysregulation in Cancer. *Nat Rev Genet* (2009) 10:704–14. doi: 10.1038/nrg2634
15. Sohel MH. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. *Achievements Life Sci* (2016) 10:175–86. doi: 10.1016/j.als.2016.11.007
16. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells◆. *J Biol Chem* (2010) 285:17442–52. doi: 10.1074/jbc.M110.107821
17. Lekchnov EA, Zaporozhchenko IA, Morozkin ES, Bryzgunova OE, Vlassov VV, Laktionov PP. Protocol for miRNA Isolation From Biofluids. *Anal Biochem* (2016) 499:78–84. doi: 10.1016/j.ab.2016.01.025
18. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in Body Fluids—The Mix of Hormones and Biomarkers. *Nat Rev Clin Oncol* (2011) 8:467–77. doi: 10.1038/nrclinonc.2011.76
19. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in Serum: A Novel Class of Biomarkers for Diagnosis of Cancer and Other Diseases. *Cell Res* (2008) 18:997–1006. doi: 10.1038/cr.2008.282
20. Di Leva G, Garofalo M, Croce CM. MicroRNAs in Cancer. *Annu Rev Pathol* (2014) 9:287–314. doi: 10.1146/annurev-pathol-012513-104715
21. Martínez-Hernández R, Dela Fuente H, Lamana A, Sampedro-Núñez M, Ramos-Levi A, Serrano-Somavilla A, et al. Utility of Circulating Serum miRNA Profiles to Evaluate the Potential Risk and Severity of Immune-Mediated Inflammatory Disorders. *J Autoimmun* (2020) 111:102472. doi: 10.1016/j.jaut.2020.102472
22. Zhao C, Dong J, Jiang T, Shi Z, Yu B, Zhu Y, et al. Early Second-Trimester Serum MiRNA Profiling Predicts Gestational Diabetes Mellitus. *PloS One* (2011) 6:e23925. doi: 10.1371/journal.pone.0023925
23. *WHO_NMH_MND_13.2_Eng.Pdf*. Available at: https://apps.who.int/iris/bitstream/handle/10665/85975/WHO_NMH_MND_13.2_eng.pdf;jsessionid=4CB78B3AD8D1F6509F2F6A82C6B99202?sequence=1 (Accessed August 27, 2021).
24. Strimbu K, Tavel JA. What Are Biomarkers? *Curr Opin HIV AIDS* (2010) 5:463–6. doi: 10.1097/COH.0b013e32833ed177
25. Yoffe L, Polsky A, Gilam A, Raff C, Mecacci F, Ognibene A, et al. Early Diagnosis of Gestational Diabetes Mellitus Using Circulating microRNAs. *Eur J Endocrinol* (2019) 181:565–77. doi: 10.1530/EJE-19-0206
26. Wander PL, Boyko EJ, Hevner K, Parikh VJ, Tadesse MG, Sorensen TK, et al. Circulating Early- and Mid-Pregnancy microRNAs and Risk of Gestational Diabetes. *Diabetes Res Clin Pract* (2017) 132:1–9. doi: 10.1016/j.diabres.2017.07.024
27. Lamadrid-Romero M, Solís KH, Cruz-Reséndiz MS, Pérez JE, Díaz NF, Flores-Herrera H, et al. Central Nervous System Development-Related microRNAs Levels Increase in the Serum of Gestational Diabetic Women

During the First Trimester of Pregnancy. *Neurosci Res* (2018) 130:8–22. doi: 10.1016/j.neures.2017.08.003

28. Zhu Y, Tian F, Li H, Zhou Y, Lu J, Ge Q. Profiling Maternal Plasma microRNA Expression in Early Pregnancy to Predict Gestational Diabetes Mellitus. *Int J Gynaecol Obstet* (2015) 130:49–53. doi: 10.1016/j.ijgo.2015.01.010

29. Cao Y-L, Jia Y-J, Xing B-H, Shi D-D, Dong X-J. Plasma microRNA-16-5p, -17-5p and -20a-5p: Novel Diagnostic Biomarkers for Gestational Diabetes Mellitus. *J Obstet Gynaecol Res* (2017) 43:974–81. doi: 10.1111/jog.13317

30. Hocaoglu M, Demirer S, Senturk H, Turgut A, Komurcu-Bayrak E. Differential Expression of Candidate Circulating microRNAs in Maternal Blood Leukocytes of the Patients With Preeclampsia and Gestational Diabetes Mellitus. *Pregnancy Hypertens* (2019) 17:5–11. doi: 10.1016/j.preghy.2019.04.004

31. Hocaoglu M, Demirer S, Loclar Karaalp I, Kaynak E, Attar E, Turgut A, et al. Identification of miR-16-5p and miR-155-5p microRNAs Differentially Expressed in Circulating Leukocytes of Pregnant Women With Polycystic Ovary Syndrome and Gestational Diabetes. *Gynecol Endocrinol* (2021) 37:216–20. doi: 10.1080/09513590.2020.1843620

32. Hromadnikova I, Kotlabova K, Dvorakova L, Krofta L. Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers With a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated With Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases. *Int J Mol Sci* (2020) 21:2437. doi: 10.3390/ijms21072437

33. Fan Y, Li W, Liu H, Wang L, Zhang S, Li W, et al. Effects of Obesity and a History of Gestational Diabetes on the Risk of Postpartum Diabetes and Hyperglycemia in Chinese Women. *Diabetes Res Clin Pract* (2019) 156:107828. doi: 10.1016/j.diabres.2019.107828

34. Sørensen AE, van Poppel MNM, Desoye G, Damm P, Simmons D, Jensen DM, et al. The Predictive Value of miR-16, -29a and -134 for Early Identification of Gestational Diabetes: A Nested Analysis of the DALI Cohort. *Cells* (2021) 10:170. doi: 10.3390/cells10010170

35. Martínez-Ibarra A, Martínez-Razo LD, Vázquez-Martínez ER, Martínez-Cruz N, Flores-Ramírez R, García-Gómez E, et al. Unhealthy Levels of Phthalates and Bisphenol A in Mexican Pregnant Women With Gestational Diabetes and Its Association to Altered Expression of miRNAs Involved With Metabolic Disease. *Int J Mol Sci* (2019) 20:3343. doi: 10.3390/ijms20133343

36. Pheiffer C, Dias S, Rheeder P, Adam S. Decreased Expression of Circulating miR-20a-5p in South African Women With Gestational Diabetes Mellitus. *Mol Diagn Ther* (2018) 22:345–52. doi: 10.1007/s40291-018-0325-0

37. Geng Y, Ju Y, Ren F, Qiu Y, Tomita Y, Tomoeda M, et al. Insulin Receptor Substrate 1/2 (IRS1/2) Regulates Wnt/β-Catenin Signaling Through Blocking Autophagic Degradation of Dishevelled2*. *J Biol Chem* (2014) 289:11230–41. doi: 10.1074/jbc.M113.544999

38. Hubal MJ, Nadler EP, Ferrante SC, Barberio MD, Suh J-H, Wang J, et al. Circulating Adipocyte-Derived Exosomal MicroRNAs Associated With Decreased Insulin Resistance After Gastric Bypass. *Obes (Silver Spring)* (2017) 25:102–10. doi: 10.1002/oby.21709

39. Gao X, Zhao S. miRNA-16-5p Inhibits the Apoptosis of High Glucose-Induced Pancreatic β Cells *via* Targeting of CXCL10: Potential Biomarkers in Type 1 Diabetes Mellitus. *Endokrynol Pol* (2020) 71:404–10. doi: 10.5603/EP.a2020.0046

40. Calimlioglu B, Karagoz K, Sevimoglu T, Kilic E, Gov E, Arga KY. Tissue-Specific Molecular Biomarker Signatures of Type 2 Diabetes: An Integrative Analysis of Transcriptomics and Protein-Protein Interaction Data. *OMICS* (2015) 19:563–73. doi: 10.1089/omi.2015.0088

41. Kwon D-N, Chang B-S, Kim J-H. MicroRNA Dysregulation in Liver and Pancreas of CMP-Neu5Ac Hydroxylase Null Mice Disrupts Insulin/PI3K-AKT Signaling. *BioMed Res Int* (2014) 2014:236385. doi: 10.1155/2014/236385

42. Assmann TS, Recamonde-Mendoza M, Costa AR, Puñales M, Tschiedel B, Canani LH, et al. Circulating miRNAs in Diabetic Kidney Disease: Case-Control Study and in Silico Analyses. *Acta Diabetol* (2019) 56:55–65. doi: 10.1007/s00592-018-1216-x

43. Lee DE, Brown JL, Rosa ME, Brown LA, Perry RA, Wiggs MP, et al. microRNA-16 Is Downregulated During Insulin Resistance and Controls

Skeletal Muscle Protein Accretion. *J Cell Biochem* (2016) 117:1775–87. doi: 10.1002/jcb.25476

44. Liu H, Wang L, Li F, Jiang Y, Guan H, Wang D, et al. The Synergistic Protection of EGCG and Quercetin Against Streptozotocin (STZ)-Induced NIT-1 Pancreatic β Cell Damage *via* Upregulation of BCL-2 Expression by miR-16-5p. *J Nutr Biochem* (2021) 96:108748. doi: 10.1016/j.jnutbio.2021.108748

45. Collares CV, Evangelista AF, Xavier DJ, Rassi DM, Arns T, Foss-Freitas MC, et al. Identifying Common and Specific microRNAs Expressed in Peripheral Blood Mononuclear Cell of Type 1, Type 2, and Gestational Diabetes Mellitus Patients. *BMC Res Notes* (2013) 6:491. doi: 10.1186/1756-0500-6-491

46. Zhang T, Ji C, Shi R. miR-142-3p Promotes Pancreatic β Cell Survival Through Targeting FOXO1 in Gestational Diabetes Mellitus. *Int J Clin Exp Pathol* (2019) 12:1529–38.

47. Kitamura T. The Role of FOXO1 in β-Cell Failure and Type 2 Diabetes Mellitus. *Nat Rev Endocrinol* (2013) 9:615–23. doi: 10.1038/nrendo.2013.157

48. Al-Rawaf HA. Circulating microRNAs and Adipokines as Markers of Metabolic Syndrome in Adolescents With Obesity. *Clin Nutr* (2019) 38:2231–8. doi: 10.1016/j.clnu.2018.09.024

49. Prats-Puig A, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Moreno M, Bonet N, et al. Changes in Circulating microRNAs are Associated With Childhood Obesity. *J Clin Endocrinol Metab* (2013) 98:E1655–1660. doi: 10.1210/jc.2013-1496

50. Prabu P, Rome S, Sathishkumar C, Aravind S, Mahalingam B, Shanthirani CS, et al. Circulating MiRNAs of 'Asian Indian Phenotype' Identified in Subjects With Impaired Glucose Tolerance and Patients With Type 2 Diabetes. *PloS One* (2015) 10:e0128372. doi: 10.1371/journal.pone.0128372

51. Liang Y-Z, Dong J, Zhang J, Wang S, He Y, Yan Y-X. Identification of Neuroendocrine Stress Response-Related Circulating MicroRNAs as Biomarkers for Type 2 Diabetes Mellitus and Insulin Resistance. *Front Endocrinol (Lausanne)* (2018) 9:132. doi: 10.3389/fendo.2018.00132

52. Karolina DS, Armugam A, Tavintharan S, Wong MTK, Lim SC, Sum CF, et al. MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus. *PloS One* (2011) 6:e22839. doi: 10.1371/journal.pone.0022839

53. Åkerman L, Casas R, Ludvigsson J, Tavira B, Skoglund C. Serum miRNA Levels are Related to Glucose Homeostasis and Islet Autoantibodies in Children With High Risk for Type 1 Diabetes. *PloS One* (2018) 13:e0191067. doi: 10.1371/journal.pone.0191067

54. Wang X, Sundquist J, Zöller B, Memon AA, Palmér K, Sundquist K, et al. Determination of 14 Circulating microRNAs in Swedes and Iraqis With and Without Diabetes Mellitus Type 2. *PloS One* (2014) 9:e86792. doi: 10.1371/journal.pone.0086792

55. Zhu H, Leung SW. Identification of microRNA Biomarkers in Type 2 Diabetes: A Meta-Analysis of Controlled Profiling Studies. *Diabetologia* (2015) 58:900–11. doi: 10.1007/s00125-015-3510-2